Brokerages Set Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Target Price at $4.79

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have earned a consensus rating of “Hold” from the eleven brokerages that are currently covering the stock, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $4.79.

A number of research analysts have issued reports on MRNS shares. Truist Financial cut Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. Oppenheimer raised shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target on the stock in a report on Monday, September 23rd. Jefferies Financial Group reissued a “hold” rating and issued a $0.50 price objective (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. TD Cowen restated a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Finally, HC Wainwright reiterated a “neutral” rating and set a $2.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th.

Institutional Trading of Marinus Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Point72 DIFC Ltd bought a new position in Marinus Pharmaceuticals during the 2nd quarter worth $28,000. SG Americas Securities LLC acquired a new stake in shares of Marinus Pharmaceuticals in the second quarter valued at about $34,000. AQR Capital Management LLC raised its position in shares of Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 12,934 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Marinus Pharmaceuticals in the second quarter worth approximately $64,000. Finally, Values First Advisors Inc. boosted its holdings in Marinus Pharmaceuticals by 501.8% in the second quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 52,257 shares during the last quarter. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Stock Performance

Shares of MRNS opened at $0.25 on Friday. Marinus Pharmaceuticals has a 52-week low of $0.23 and a 52-week high of $11.26. The firm has a market cap of $13.67 million, a price-to-earnings ratio of -0.10 and a beta of 1.25. The business’s fifty day moving average is $0.66 and its 200-day moving average is $1.15.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.